On 17 occasions, RA Capital bought shares in biotech company financings after having sold short shares of the same company when it was supposed to be restricted from doing so.
Patients lost 12% of their body weight following 12 weeks of treatment with Arena's Belviq plus phentermine.
Avanir Pharmaceuticals are surging Monday after demonstrating once again that cough syrup produces a nice, mellow high
NPS Pharmaceuticals shares are weak Monday following a rough outing for its hormone replacement therapy Natpara at an FDA advisory panel on Friday.
Amarin evaluating next steps following FDA's decision to denial reinstatement of Vascepa SPA for 'Anchor" indication.
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
Orexigen's Contrave must prove it can top the dismal obesity pill launches of its competitors Arena and Vivus.
Language in the new Xtandi label should help Medivation and Astellas widen their market share lead over Johnson & Johnson's competing prostate cancer drug Zytiga.
Meacham is taking a new job at Barclays where he will cover biotech and pharma stocks.
Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.